Provided by Tiger Fintech (Singapore) Pte. Ltd.

Harmony Biosciences Holdings, Inc.

32.42
-0.7700-2.32%
Pre-market: 32.41-0.0100-0.03%04:45 EDT
Volume:581.85K
Turnover:18.92M
Market Cap:1.86B
PE:12.92
High:33.25
Open:33.00
Low:32.01
Close:33.19
Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-  Eli Lilly, Krispy Kreme, PayPal

Reuters
·
25 Feb

Harmony Biosciences Holdings, Inc. (HRMY) Tops Q4 Earnings and Revenue Estimates

Zacks
·
25 Feb

Harmony Biosciences Price Target Maintained With a $50.00/Share by Needham

Dow Jones
·
25 Feb

BUZZ-Harmony Biosciences rises on quarterly profit and sales beat

Reuters
·
25 Feb

Harmony Biosciences' Q4 Adjusted Earnings, Net Product Revenue Rise

MT Newswires Live
·
25 Feb

Earnings Flash (HRMY) Harmony Biosciences Posts Q4 Net Product Revenue $201.3M, vs. FactSet Est of $201M

MT Newswires Live
·
25 Feb

Harmony Biosciences Q4 Adj $1.08 Beats $0.74 Estimate, Sales $201.27M Beat $201.25M Estimate

Benzinga
·
25 Feb

BRIEF-Harmony Biosciences Q4 Net Income USD 49.475 Million

Reuters
·
25 Feb

Harmony Biosciences: Reiterates 2025 Net Revenue Guidance

THOMSON REUTERS
·
25 Feb

Harmony Biosciences Q4 Operating Income USD 55.727 Million

THOMSON REUTERS
·
25 Feb

Harmony Biosciences Qtrly Adj EPS $1.08

THOMSON REUTERS
·
25 Feb

Harmony Biosciences Holdings Inc Q4 Shr View $0.74, REV View $201.0 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
25 Feb

Harmony Biosciences Qtrly Net Product Revenues $201.3 Million

THOMSON REUTERS
·
25 Feb

Harmony Biosciences Holdings Inc FY2025 REV View $848.5 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
25 Feb

Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs

Business Wire
·
25 Feb

Is Harmony Biosciences (HRMY) the Oversold Biotech Stock to Buy Now?

Insider Monkey
·
25 Feb

Harmony Biosciences (HRMY) Upgraded to Strong Buy: Here's Why

Zacks
·
25 Feb

5 High Earnings Yield Value Stocks to Buy Amid Market Volatility

Zacks
·
24 Feb

Harmony Biosciences Holdings Inc expected to post earnings of 74 cents a share - Earnings Preview

Reuters
·
21 Feb

Mizuho Adjusts Price Target on Harmony Biosciences to $42 From $52, Keeps Outperform Rating

MT Newswires Live
·
20 Feb